DVDMS sensitizer for cancer sonodynamic therapy
View Patent ↗A method for treatment of hyperproliferative tissue by injection of and subsequently exposing the hyperproliferative tissue to a frequency of ultrasound. The invention further includes purified bis [1-[6,7-bis [2-(sodium carbonate ethyl]-1,3,5,8,-tetramethyl-2-vinyl-porphin-4-yl]ethyl]ether (DVDMS) for use in sonodynamic treatment of hyperproliferative tissue including cancer and further includes a kit including a dosage controllable injection device charged with a biologically compatible fluid containing DVDMS.
1. A method for treatment of hyperproliferative tissue in vivo by i.v. injection of purified bis [1-[6,7-bis [2-(sodium carbonate ethyl]-1,3,5,8-tetramethyl-2-vinyl-porphin-4-yl] ethyl] ether (DVDMS) in a biocompatible liquid at 0.1 to 0.5 mg of DVDMS per kg of body weight and subsequently exposing the hyperproliferative tissue to an ultrasound frequency of 0.25 to 1.25 MHz at a power 0.0.1 to 1.5 W/cm 2 to obtain what appears by Mill to be complete remission.
2. The method of claim 1 wherein the purity of DVDMS is at least 95%.
3. The method of claim 2 wherein the injection is by IV at a dosage of from 0.15 to 0.25 mg/kg and the hyperproliferative tissue is tumor tissue.
4. The method of claim 3 wherein the sonic frequency is from 0.5 to 1 MHz and the ultrasound power is from 0.1 W/cm 2 to 1.5 W/cm 2 .
5. The method of claim 4 where the time of treatment is 20 to 30 minutes 1.5 to 2.5 hours post injection.
6. Purified bis [1-[6,7-bis [2-(sodium carbonate ethyl]-1,3,5,8, tetramethyl-2-vinyl-porphin-4-yl] ethyl] ether (DVDMS) for use in sonodynamic therapy where the purity is at least 98%.
7. The method of claim 3 wherein the tumor tissue is brain stem tumor tissue.
8. The method of claim 1 where the dosage is 0.15 to 0.25 mg/kg.
9. The method of claim 7 where the time of treatment is 20 to 30 minutes 1.5 to 2.5 hours post injection.